Bioquímica y Biotecnología
BBT
Hospital de Cruces
Barakaldo, EspañaPublicaciones en colaboración con investigadores/as de Hospital de Cruces (3)
2017
-
Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B
Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 4, pp. 636-642
2010
-
BRCA1 5272-1G>A and BRCA2 5374delTATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin
Clinical Genetics, Vol. 77, Núm. 1, pp. 60-69
-
MLH1 founder mutations with moderate penetrance in Spanish Lynch syndrome families
Cancer Research, Vol. 70, Núm. 19, pp. 7379-7391